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Introduction {#cam4608-sec-0001}
============

The majority of women with in situ and early‐stage breast cancer receive adjuvant breast radiation therapy (RT) after breast‐conserving surgery. Breast RT is generally well tolerated, but acute skin toxicity is a common side effect which can result in bothersome symptoms including burning sensation, itching, tenderness, and pain. In some cases, the skin reaction can progress to desquamation, either dry or moist, which is often more uncomfortable and poses a risk, albeit small, of infection and/or treatment breaks. Mild erythema is very common, occurring in up to 95% of patients, as is brisk erythema with or without moist desquamation, ranging from 5% to 69%, whereas moist desquamation is less common, ranging from 11% to 47% [1](#cam4608-bib-0001){ref-type="ref"}, [2](#cam4608-bib-0002){ref-type="ref"}, [3](#cam4608-bib-0003){ref-type="ref"}, [4](#cam4608-bib-0004){ref-type="ref"}, [5](#cam4608-bib-0005){ref-type="ref"}, [6](#cam4608-bib-0006){ref-type="ref"}, [7](#cam4608-bib-0007){ref-type="ref"}, [8](#cam4608-bib-0008){ref-type="ref"}. Several predictive factors for more severe skin toxicity have been identified, including body mass index (BMI), breast size, and radiation technique including fractionation regimen and dosimetric homogeneity [1](#cam4608-bib-0001){ref-type="ref"}, [4](#cam4608-bib-0004){ref-type="ref"}, [6](#cam4608-bib-0006){ref-type="ref"}, [7](#cam4608-bib-0007){ref-type="ref"}, [8](#cam4608-bib-0008){ref-type="ref"}, [9](#cam4608-bib-0009){ref-type="ref"}.

Our institution serves a racially and ethnically diverse population of breast cancer patients, and we have been interested in studying racial and ethnic variation in radiation‐related skin toxicity in breast cancer patients. We previously published a series evaluating predictors of skin toxicity in a cohort of patients receiving postmastectomy radiation (PMRT), and identified black/AA race, postmenopausal status, and higher BMI as predictors for moist desquamation [10](#cam4608-bib-0010){ref-type="ref"}. Interestingly, these same factors did not predict for higher grade skin toxicity by the National Cancer Institute\'s Common Toxicity Criteria for Adverse Events (CTCAE) skin toxicity scale, which does not clearly differentiate between patients who do and do not develop moist desquamation. The observed variation in skin toxicity in that series was thus seen primarily in rate of moist desquamation, rather than other skin toxicity characteristics such as the degree of erythema. Moist desquamation is much less common in patients receiving radiation to the intact breast after lumpectomy, as compared to patients receiving radiation to the chest wall after mastectomy. We therefore sought to determine if the same factors, particularly race, predicted for more severe skin toxicity in the setting of radiation to the intact breast in a similarly diverse cohort of patients from the same institution.

Materials and Methods {#cam4608-sec-0002}
=====================

In this study, we evaluated 392 consecutive breast cancer patients enrolled during December, 2008 to July, 2014 in a prospective study assessing RT‐induced skin toxicity to the intact breast in the Radiation Oncology Department at the University of Miami. The study was approved by the Institutional Review Board. Women (≥18 years) with newly diagnosed breast carcinoma, stage 0--III (American Joint Committee on Cancer) who underwent breast‐conserving surgery were scheduled to receive RT to the intact breast with or without regional nodal radiation were eligible. At the time of enrollment, patients signed informed consent either in English or Spanish, and completed a baseline assessment form, including self‐identification of race and ethnicity, breast cancer risk factors including reproductive and family history, as well as comorbidities, height, weight, and smoking habits. Other patient, disease, and treatment characteristics, including detailed information on radiation delivery, were prospectively collected.

Skin toxicity was assessed by the treating physician. As previously described [10](#cam4608-bib-0010){ref-type="ref"}, we used both NCI CTCAE (v3.0), and a modified variation in the NCI CTCAE (v3.0) skin toxicity scale which breaks CTCAE "grade 2" into three subcategories, seeking to capture more detailed information including the presence and extent of dry and moist desquamation. The scale divides skin reaction into six categories as follows: 1 -- faint or dull erythema and/or follicular reaction and/or itching (CTCAE grade 1); 2 -- bright erythema and/or tender to touch (CTCAE grade 2); 3 -- dry desquamation with or without erythema (CTCAE grade 1 or 2); 4 -- small or moderate amount of wet desquamation (CTCAE grade 2); 5 -- confluent moist desquamation (CTCAE grade 3); 6 -- ulceration, hemorrhage, and/or necrosis (CTCAE grade 4). Skin toxicity was captured at midpoint and at the completion of RT. In general, the duration of RT was 4 or 6 weeks depending on the fractionation scheme used. The patients in our cohort were uniformly managed with topical aloe vera applied to the breast throughout treatment, with silver sulfadiazine applied to areas of desquamation as needed.

We used Pearson\'s chi‐squared test or Fisher\'s exact test to compare differences in the distributions of patient and disease characteristics as well as skin toxicity grade by race/ethnicity. Wilcoxon signed‐rank test was performed to evaluate progression of RT‐induced skin toxicity from midpoint to RT completion. Multiple logistic regression analyses were conducted to evaluate the association between multiple predictors and the risk of higher grade skin toxicity using both grading scales. Statistical analysis was performed using SAS version 9.3 for Windows (SAS Institute, Cary, NC) and significance level was set at two‐sided *α* = 0.05.

Results {#cam4608-sec-0003}
=======

Patient demographic and tumor characteristics {#cam4608-sec-0004}
---------------------------------------------

In Table [1](#cam4608-tbl-0001){ref-type="table-wrap"}, we summarize overall patient, tumor, and treatment characteristics by race and ethnicity, presented as 15% non‐Hispanic white (NHW), 62% Hispanic white (HW), 20% AA, and 3% other, as well as condensed to 80% non‐AA and 20% AA. Mean age at the time of enrollment was 56.2 years (range 27--85 years). Thirty‐three percent were pre or perimenopausal, and 67% postmenopausal. A higher proportion of AA patients were obese (61% vs. 35% in non‐AA; *P* \< 0.001), had at least two comorbidities (31% vs. 22%; *P* = 0.013), had stage II‐III disease (43% vs. 28%; *P* = 0.022), had ER‐negative tumors (34% vs. 21%; *P* = 0.013) or triple‐negative tumors (27% vs. 12%; *P* \< 0.001), and had above‐median breast volume (72% vs. 45%; *P* \< 0.001).

###### 

Patient characteristics by race/ethnicity

  Variable                                                        Total         NHW           HW            AA            Other         *P* [a](#cam4608-note-0003){ref-type="fn"}   Non‐AA        AA   *P* [a](#cam4608-note-0003){ref-type="fn"}                                          
  --------------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- -------------------------------------------- ------------- ---- -------------------------------------------- ---- ------------ ----- ---- ---- ---- ------------
  Study population                                                392           100           59            15            241           62                                           79            20   13                                           3                 313   80   79   20   
  Age at consent (years)                                                                                                                                                                                                                                                                    
  \<50                                                            98            25            18            30            58            24                                           20            25   2                                            15   0.776        78    25   20   25   0.733
  50--59                                                          156           40            21            36            94            39                                           34            43   7                                            54   122          39    34   43        
  ≥60                                                             138           35            20            34            89            37                                           25            32   4                                            31   113          36    25   32        
  Mean (SD)                                                       56.2 (9.1)    55.9 (9.1)    56.5 (9.0)    55.5 (9.4)    57.9 (1.1)    56.4 (9.1)                                   55.5 (9.4)                                                                                             
  Menopausal status                                                                                                                                                                                                                                                                         
  Pre/Peri                                                        128           33            24            41            76            32                                           25            32   3                                            23   0.392        103   33   25   32   0.831
  Post                                                            264           67            35            59            165           68                                           54            68   10                                           77   210          67    54   68        
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                             
  \<25                                                            101           26            28            47            55            23                                           13            16   5                                            38   **≤0.001**   88    28   13   16   **≤0.001**
  25--29.99                                                       133           34            17            29            94            39                                           18            23   4                                            31   115          37    18   23        
  ≥30                                                             158           40            14            24            92            38                                           48            61   4                                            31   110          35    48   61        
  Mean (SD)                                                       29.4 (6.4)    27.0 (6.6)    29.0 (5.2)    32.5 (8.4)    28.6 (6.7)    28.6 (5.6)                                   32.5 (8.4)                                                                                             
  Smoking history                                                                                                                                                                                                                                                                           
  Never                                                           260           66            38            64            156           65                                           56            71   10                                           77   0.583        204   65   56   71   0.337
  Ever                                                            132           34            21            36            85            35                                           23            29   3                                            23   109          35    23   29        
  Number of comorbidities[b](#cam4608-note-0004){ref-type="fn"}                                                                                                                                                                                                                             
  0                                                               154           39            27            46            102           42                                           20            25   5                                            38   0.066        134   43   20   25   **0.013**
  1                                                               146           37            20            34            87            36                                           35            44   4                                            31   111          35    35   44        
  2                                                               66            17            7             12            36            15                                           20            26   3                                            23   46           15    20   26        
  ≥3                                                              26            7             5             8             16            7                                            4             5    1                                            8    22           7     4    5         
  Disease stage                                                                                                                                                                                                                                                                             
  0                                                               79            20            7             12            53            22                                           15            19   4                                            31   **0.013**    64    20   15   19   **0.022**
  I                                                               193           49            38            64            120           50                                           30            38   5                                            38   163          52    30   38        
  II--III                                                         120           31            14            24            68            28                                           34            43   4                                            31   86           28    34   43        
  Histology                                                                                                                                                                                                                                                                                 
  DCIS (ductal carcinoma in situ)                                 85            22            8             14            57            24                                           16            20   4                                            31   0.692        69    22   16   20   0.954
  IDC (invasive ductal carcinoma)                                 289           74            48            81            172           71                                           60            76   9                                            69   229          73    60   76        
  ILC (invasive lobular carcinoma)                                17            4             3             5             11            5                                            3             4    --                                           --   14           5     3    4         
  Other                                                           1             0             --            --            1             0                                            --            --   --                                           --   1            0     --   --        
  ER                                                                                                                                                                                                                                                                                        
  Positive                                                        299           76            43            73            193           80                                           52            66   11                                           85   **0.025**    247   79   52   66   **0.013**
  Negative                                                        92            24            16            27            47            20                                           27            34   2                                            15   65           21    27   34        
  PR                                                                                                                                                                                                                                                                                        
  Positive                                                        263           67            37            63            169           71                                           48            61   9                                            69   0.186        215   69   48   61   0.156
  Negative                                                        127           33            22            37            70            29                                           31            39   4                                            31   96           31    31   39        
  HER2                                                                                                                                                                                                                                                                                      
  Positive                                                        38            12            5             9             24            12                                           8             12   1                                            11   0.791        30    12   8    12   0.920
  Negative                                                        285           88            50            91            169           88                                           58            88   8                                            89   227          88    58   88        
  Triple negative                                                                                                                                                                                                                                                                           
  No                                                              317           85            48            86            201           89                                           57            73   11                                           85   **0.003**    260   88   57   73   **≤0.001**
  Yes                                                             56            15            8             14            25            11                                           21            27   2                                            15   35           12    21   27        
  Chemotherapy therapy                                                                                                                                                                                                                                                                      
  No                                                              191           49            28            48            119           49                                           41            52   3                                            23   0.869        150   48   41   52   0.306
  Yes                                                             201           51            31            52            122           51                                           38            48   10                                           77   163          52    38   48        
  Hormone therapy                                                                                                                                                                                                                                                                           
  No                                                              133           34            17            29            75            31                                           40            51   1                                            8    **0.004**    93    30   40   51   **≤0.001**
  Yes                                                             257           66            42            71            165           69                                           39            49   11                                           92   218          70    39   49        
  Fractionation                                                                                                                                                                                                                                                                             
  Hypofractionated                                                67            17            12            21            41            17                                           12            15   2                                            15   0.698        55    18   12   15   0.560
  Conventionally fractionated                                     323           83            46            79            199           83                                           67            85   11                                           85   256          82    67   85        
  Lumpectomy cavity boost                                                                                                                                                                                                                                                                   
  No                                                              48            12            4             7             29            12                                           13            17   2                                            15   0.239        35    11   13   17   0.209
  Yes                                                             342           88            54            93            211           88                                           66            83   11                                           85   276          89    66   83        
  Breast volume (cc)                                                                                                                                                                                                                                                                        
  \<881.3 (Median)                                                193           50            37            64            125           53                                           22            28   9                                            69   **≤0.001**   171   55   22   28   **≤0.001**
  ≥881.3                                                          193           50            21            36            112           47                                           56            72   4                                            31   137          45    56   72        
  Mean (SD)                                                       999 (534)     820 (479)     976 (484)     1219 (638)    906 (583)     944 (990)                                    1219 (638)                                                                                             
  Percentage of breast volume with \>105% prescription dose                                                                                                                                                                                                                                 
  \<51.3 (75th percentile)                                        261           75            38            69            159           76                                           57            79   7                                            58   0.419        204   74   57   79   0.337
  ≥51.3                                                           88            25            17            31            51            24                                           15            21   5                                            42   73           26    15   21        
  Mean (SD)                                                       34.9 (24.8)   38.2 (26.1)   34.2 (24.6)   31.6 (24.5)   51.8 (17.5)   35.7 (24.9)                                  31.6 (24.5)                                                                                            
  Percentage of breast volume with \>110% prescription dose                                                                                                                                                                                                                                 
  0                                                               184           53            28            51            114           54                                           39            54   3                                            25   0.889        145   52   39   54   0.805
  \>0                                                             164           47            27            49            95            46                                           33            46   9                                            75   131          48    33   46        
  Mean (SD)                                                       16.1 (23.0)   24.3 (22.8)   13.5 (22.5)   16.1 (24.4)   18.8 (21.9)   16.1 (22.7)                                  16.1 (24.4)                                                                                            

AA, Black or African American; HW, Hispanic white; NHW, non‐Hispanic white; SD, standard deviation; %, column percentage, except for table first row showing row percentage (distribution of study population by race/ethnicity).

*P*‐value from chi‐squared test or Fisher\'s exact test excluding other race category and missing.

Sum of 11 patient‐reported comorbidity conditions: diabetes, hypertension, heart disease, lung disease, thyroid condition, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, etc.

Bold values indicate statistically significant findings at p \< 0.05.

John Wiley & Sons, Ltd

Treatment characteristics {#cam4608-sec-0005}
-------------------------

All patients received breast‐conserving surgery, and patients with invasive disease had axillary dissection or sentinel node biopsy. As shown in Table [1](#cam4608-tbl-0001){ref-type="table-wrap"}, 51% received systemic chemotherapy (8% neo‐adjuvant and 43% adjuvant) and 66% received hormone therapy. A higher proportion of AA patients did not receive hormone therapy (51% vs. 30%; *P* \< 0.001). RT was delivered to the breast with or without regional nodes based on clinical indications. Patients were treated using standard or partially wide photon tangents with both conventionally fractionated and hypofractionated schemes. The dose range to the breast was 42.4--50.4 Gy, in fraction sizes of 1.8--2.7 Gy. The most common conventionally fractionated approach was 50 Gy in 2 Gy per fraction, and the most common hypofractionated approach was 42.4 Gy in 2.65 Gy per fraction. For the purposes of statistical analysis, total dose of \<45 Gy in fraction size \>2 Gy was considered hypofractionated, and total dose ≥45 Gy in fraction size of ≤2 Gy was considered conventionally fractionated.

Seventeen percent of patients were treated with a hypofractionated approach, and 83% with a conventionally fractionated approach. Regional nodal radiation including supra/infraclavicular nodes +/− axillary and intern al mammary nodes was delivered in 15% of patients, dose range 45--50.4 Gy in 25 fractions. Anterior oblique supraclavicular +/− axillary fields were most commonly matched monoisocentrically with the breast tangents. Eighty‐eight percent of patients received a boost to the lumpectomy cavity of 10--16 Gy. Planning was completed on the Eclipse or Pinnacle planning system depending on the institutional center, and forward planned field‐in‐field technique was used to maximize dose homogeneity. Dosimetric analysis showed that the mean percentage breast volume receiving \>105% of prescription dose was 35% and \>110% was 16%. There were no significant differences in RT treatment parameters by race or ethnicity.

Skin toxicity {#cam4608-sec-0006}
-------------

Table [2](#cam4608-tbl-0002){ref-type="table-wrap"} demonstrates the progression of skin toxicity grades from midpoint to RT completion (*P* \< 0.001). Using the modified grading scale, changes in skin toxicity from midpoint to RT completion were: (1) grade 0: decreased from 11% to 1%; (2) grade 1 (mild erythema): decreased from 82% to 42%; (3) grade 2 (brisk erythema without desquamation): increased from 4% to 20%; (4) grade 3 (dry desquamation with or without erythema): increased from 1% to 15%; (5) grade 4 (moist desquamation with or without erythema): increased from 3% to 20%; (6) grade 5 (confluent moist desquamation): increased from 0% to 2%. Using the NCI CTCAE grading scale, changes in skin toxicity from midpoint to RT completion were as follows: (1) grade 0: decreased from 11% to 1%; (2) grade 1: decreased from 83% to 46%; (3) grade 2: increased from 6% to 51%; and (4) grade 3: increased from 0% to 2%. No patient developed grade 6 by the modified study scale or grade 4 or greater by CTCAE scale at RT completion.

###### 

Progression of skin toxicity from RT midpoint to post‐RT

  Skin toxicity at RT midpoint (modified grade)   Skin toxicity at post‐RT (modified grade)                                                                     
  ----------------------------------------------- ------------------------------------------- ----------- ---------- ---------- ---------- -------- ----------- ------------
  0                                               2                                           19          5          11         5          1        43 (11%)    **≤0.001**
  1                                               1                                           140         63         43         58         7        312 (82%)   
  2                                               --                                          1           6          3          3          --       13 (4%)     
  3                                               --                                          --          --         1          2          --       3 (1%)      
  4                                               --                                          --          2          --         6          1        9 (3%)      
  Total                                           3 (1%)                                      160 (42%)   76 (20%)   58 (15%)   74 (20%)   9 (2%)   380         

  Skin toxicity at RT midpoint (CTCAE grade)   Skin toxicity at post‐RT (CTCAE grade)                                                          
  -------------------------------------------- ---------------------------------------- ----------- ----------- -------- ---- ---- ----------- ------------
  0                                            2                                        24          16          1        --   --   43 (11%)    **≤0.001**
  1                                            1                                        149         157         7        --   --   314 (83%)   
  2                                            --                                       1           21          1        --   --   23 (6%)     
  Total                                        3 (1%)                                   174 (46%)   194 (51%)   9 (2%)   --   --   380         

Wilcoxon signed‐rank test.

Bold values indicate statistically significant findings at p \< 0.05.

John Wiley & Sons, Ltd

Table [3](#cam4608-tbl-0003){ref-type="table-wrap"} presents skin toxicity at RT completion using both the modified scale of 0--6, as well as the NCI CTCAE scale of 0--4, broken down by patient, disease, and treatment characteristics. In general, the two scales identified similar predictors of more severe skin toxicity, including higher BMI, more advance tumor stage and invasive ductal histology, progesterone receptor (PR) negative status, conventionally fractionated regimens with RT dose to whole breast ≥45 Gy, the use of a lumpectomy cavity boost, and above‐median breast volume. Breast volume and BMI were significantly correlated. Neither race nor ethnicity predicted for more severe skin toxicity grade, although there was a higher crude rate of severe skin reaction in AA patients compared to non‐AA: 28 versus 19% for modified grade 4--5 (moist desquamation) and 58 versus 50% for CTCAE grade 2--3 toxicity. Skin toxicity grade did not vary with age, menopausal status, the use of chemotherapy, and dosimetric factors.

###### 

Skin toxicity grade at post‐RT by patient and clinical variables

                                                              Skin toxicity (modified grade)   Skin toxicity (CTCAE grade)                                                                                                                                          
  ----------------------------------------------------------- -------------------------------- ----------------------------- ---- ---- ---- ---- ----------- ----- ----- ----- ---- ---- ---- ----------- ----- ----- ----- ---- ----------- ----- ----- ----- ---- -----------
  Total patients                                              4                                169                           77   59   74   9                173   44    136   35   83   21               4     184   195   9                188   48    204   52   
  Age at consent (years)                                                                                                                                                                                                                                            
  \<50                                                        --                               39                            15   18   24   2    0.221       39    40    33    34   26   27   0.367       --    43    53    2    0.308       43    44    55    56   0.332
  50--59                                                      1                                65                            37   23   24   6    66          42    60    38    30   19   1    71          78    6     72    46   84          54                     
  ≥60                                                         3                                65                            25   18   26   1    68          49    43    31    27   20   3    70          64    1     73    53   65          47                     
  Menopausal status                                                                                                                                                                                                                                                 
  Pre/Peri                                                    --                               56                            19   23   27   3    0.433       56    44    42    33   30   23   0.719       --    61    64    3    0.996       61    48    67    52   0.933
  Post                                                        4                                113                           58   36   47   6    117         44    94    36    53   20   4    123         131   6     127   48   137         52                     
  Race/ethnicity                                                                                                                                                                                                                                                    
  NHW                                                         --                               28                            17   7    6    1    NE          28    47    24    41   7    12   0.451       --    31    27    1    0.286       31    53    28    47   0.610
  HW                                                          2                                107                           41   40   48   3                109   45    81    34   51   21               2     116   120   3                118   49    123   51   
  AA                                                          2                                28                            16   11   17   5                30    38    27    34   22   28               2     31    41    5                33    42    46    58   
  Other                                                       --                               6                             3    1    3    --               6     46    4     31   3    23               --    6     7     --               6     46    7     54   
  Non‐AA                                                      2                                141                           61   48   57   4    0.080       143   46    109   35   61   19   0.230       2     153   154   4    **0.019**   155   50    158   50   0.218
  AA                                                          2                                28                            16   11   17   5                30    38    27    34   22   28               2     31    41    5                33    42    46    58   
  BMI (kg/m^2^)                                                                                                                                                                                                                                                     
  \<25                                                        ‐                                56                            18   15   10   2    **0.008**   56    55    33    33   12   12   **0.001**   ‐     62    37    2    **0.004**   62    61    39    39   **0.002**
  25--29.99                                                   1                                62                            28   20   21   1    63          47    48    36    22   17   1    63          68    1     64    48   69          52                     
  ≥30                                                         3                                51                            31   24   43   6    54          34    55    35    49   31   3    59          90    6     62    39   96          61                     
  Smoking history                                                                                                                                                                                                                                                   
  Never                                                       2                                111                           45   39   56   7    0.227       113   43    84    32   63   24   0.093       2     121   130   7    0.738       123   47    137   53   0.717
  Ever                                                        2                                58                            32   20   18   2    60          45    52    39    20   15   2    63          65    2     65    49   67          51                     
  No. of comorbidities                                                                                                                                                                                                                                              
  None                                                        1                                67                            34   25   24   3    NE          68    44    59    38   27   18   0.821       1     72    78    3    0.642       73    47    81    53   0.993
  1                                                           --                               66                            27   20   31   2                66    45    47    32   33   23               --    71    73    2                71    49    75    51   
  2                                                           3                                25                            10   12   14   2                28    42    22    33   16   24               3     29    32    2                32    48    34    52   
  ≥3                                                          --                               11                            6    2    5    2                11    42    8     31   7    27               --    12    12    2                12    46    14    54   
  Disease stage                                                                                                                                                                                                                                                     
  0                                                           2                                45                            11   10   10   1    0.099       47    59    21    27   11   14   **0.013**   2     47    29    1    **0.022**   49    62    30    38   **0.005**
  IA--B                                                       1                                83                            35   29   40   5                84    44    64    33   45   23   1           92    95    5     93   48          100   52               
  IIA--IIIC                                                   1                                41                            31   20   24   3                42    35    51    43   27   23   1           45    71    3     46   38          74    62               
  Histology                                                                                                                                                                                                                                                         
  DCIS (ductal carcinoma in situ)                             2                                49                            10   11   11   2    NE          51    60    21    25   13   15   **0.004**   2     51    30    2    NE          53    62    32    38   **0.002**
  IDC (invasive ductal carcinoma)                             2                                108                           64   47   61   7                110   38    111   38   68   24   2           121   159   7          123         43    166   57         
  ILC (invasive lobular carcinoma)                            --                               11                            3    1    2    --               11    65    4     24   2    12   --          11    6     --         11          65    6     35         
  Other                                                       --                               1                             --   --   --   --               1     100   --    --   --   --   --          1     --    --         1           100   --    --         
  ER                                                                                                                                                                                                                                                                
  Positive                                                    3                                133                           54   46   55   8    0.493       136   45    100   33   63   21   0.518       3     145   143   8    0.275       148   49    151   51   0.233
  Negative                                                    1                                35                            23   13   19   1    36          39    36    39    20   22   1    38          52    1     39    42   53          58                     
  PR                                                                                                                                                                                                                                                                
  Positive                                                    3                                123                           46   38   46   7    0.150       126   48    84    32   53   20   0.063       3     133   120   7    **0.044**   136   52    127   48   **0.022**
  Negative                                                    1                                44                            31   21   28   2    45          35    52    41    30   24   1    49          75    2     50    39   77          61                     
  HER2                                                                                                                                                                                                                                                              
  Positive                                                    --                               17                            7    6    8    --   0.836       17    45    13    34   8    21   0.855       --    19    19    --   0.503       19    50    19    50   0.500
  Negative                                                    2                                112                           62   43   58   8    114         40    105   37    66   23   2    124         151   8     126   44   159         56                     
  Triple negative                                                                                                                                                                                                                                                   
  No                                                          3                                140                           60   48   58   8    0.336       143   45    108   34   66   21   0.192       3     153   153   8    0.145       156   49    161   51   0.062
  Yes                                                         --                               18                            15   8    14   1    18          32    23    41    15   27   --   20          35    1     20    36   36          64                     
  Chemotherapy                                                                                                                                                                                                                                                      
  No                                                          3                                86                            37   27   34   4    0.909       89    47    64    34   38   20   0.622       3     91    93    4    0.604       94    49    97    51   0.628
  Yes                                                         1                                83                            40   32   40   5    84          42    72    36    45   22   1    93          102   5     94    47   107         53                     
  Hormone therapy                                                                                                                                                                                                                                                   
  No                                                          --                               56                            27   20   27   3    0.966       56    42    47    35   30   23   0.784       --    60    70    3    0.668       60    45    73    55   0.379
  Yes                                                         4                                113                           49   39   46   6    117         46    88    34    52   20   4    124         123   6     128   50   129         50                     
  Fractionation                                                                                                                                                                                                                                                     
  Hypofractionated                                            2                                46                            10   4    5    --   **≤.001**   48    72    14    21   5    7    **≤.001**   2     47    18    --   **≤.001**   49    73    18    27   **≤.001**
  Conventionally fractionated                                 2                                122                           67   54   69   9    124         38    121   37    78   24   2    135         177   9     137   42   186         58                     
  Lumpectomy cavity boost                                                                                                                                                                                                                                           
  No                                                          1                                30                            5    5    5    2    **0.024**   31    65    10    21   7    15   **0.009**   1     31    14    2    **0.008**   32    67    16    33   **0.005**
  Yes                                                         3                                138                           72   53   69   7    141         41    125   37    76   22   3    151         181   7     154   45   188         55                     
  Breast volume                                                                                                                                                                                                                                                     
  \<881.3 CC (median)                                         4                                94                            34   30   27   1    **0.005**   99    51    66    34   28   15   **0.003**   4     100   85    1    **0.003**   105   54    88    46   **0.011**
  ≥881.3 CC                                                   --                               73                            42   28   43   8    73          38    67    35    53   27   --   80          106   8     80    41   113         59                     
  Percentage of breast volume with \>105% prescription dose                                                                                                                                                                                                         
  \<51.3 (75th percentile)                                    3                                118                           48   42   45   5    0.607       121   46    90    34   50   19   0.438       3     126   127   5    0.581       129   49    132   51   0.644
  ≥51.3                                                       1                                43                            15   9    19   1    44          50    24    27    20   23   1    45          41    1     46    52   42          48                     
  Percentage of breast volume with \>110% prescription dose                                                                                                                                                                                                         
  0                                                           2                                89                            29   29   33   2    0.634       91    49    58    32   35   19   0.710       2     94    86    2    0.350       96    52    88    48   0.456
  \>0                                                         2                                72                            33   22   31   4    74          45    55    34    35   21   2    77          81    4     79    48   85          52                     

NE, not estimable.

*P*‐value from chi‐squared test or Fisher\'s exact test with grade 0--1 grouped.

*P*‐value from chi‐squared test or Fisher\'s exact test.

Bold values indicate statistically significant findings at p \< 0.05.

John Wiley & Sons, Ltd

As shown in Table [4](#cam4608-tbl-0004){ref-type="table-wrap"}, multivariate analyses were performed to evaluate the association between skin toxicity and age, race, breast volume, BMI, stage, ER and PR status, fractionation approach, and breast volume. For the modified scale, analysis was performed for two separate groupings, grade 2--3 versus 0--1, and 4--5 versus 0--1; the first grouping separates patients with lower versus higher degrees of erythema or hyperpigmentation, whereas the latter specifically separates out patients with moist desquamation. For grade 2--3 versus 0--1, the following factors were significant: higher stage (OR = 1.82, 95% CI = 1.00, 3.31), ER‐positive/PR‐negative status (OR = 3.00 95% CI = 1.25, 7.21), and conventionally fractionated regimens (OR = 2.98; 95% CI = 1.52, 5.84); higher BMI was not significantly associated with higher grade toxicity. For 4--5 versus 0--1, higher BMI (OR = 2.99, 95% CI = 1.29, 6.92), ER‐positive/PR‐negative status (OR = 3.50, 95% CI = 1.29, 9.48), and conventionally fractionated regimens (OR = 4.81, 95% CI = 1.77, 13.05) were significantly associated with higher grade skin toxicity‐ specifically moist desquamation.

###### 

Associations between multiple variables and post‐RT skin toxicity

  Variable                    Category                   Skin toxicity (modified grade)   Skin toxicity (CTCAE Grade)                                                                
  --------------------------- -------------------------- -------------------------------- ----------------------------- -------------------- ------------------- ------------------- -----------
  Age at enrollment (years)   \<50 versus ≥50            1.02 (0.57, 1.81)                0.948                         1.44 (0.75, 2.75)    0.276               1.12 (0.67, 1.86)   0.670
  Race                        AA versus Non‐AA           0.95 (0.50, 1.78)                0.861                         1.13 (0.56, 2.29)    0.735               1.01 (0.58, 1.76)   0.975
  BMI                         25--29.99 versus \<25      1.32 (0.71, 2.47)                0.378                         1.62 (0.70, 3.77)    0.262               1.84 (1.03, 3.27)   **0.038**
  ≥30 versus \<25             1.53 (0.79, 2.98)          0.210                            2.99 (1.29, 6.92)             **0.011**            2.09 (1.15, 3.82)   **0.016**           
  Stage                       I--III versus 0            1.82 (1.00, 3.31)                **0.050**                     2.10 (0.98, 4.50)    0.058               1.82 (1.06, 3.11)   **0.029**
  ER/PR                       ER+/PR− versus ER+/PR+     3.00 (1.25, 7.21)                **0.014**                     3.50 (1.29, 9.48)    **0.014**           2.74 (1.26, 5.98)   **0.001**
  ER−/PR− versus ER+/PR+      1.66 (0.93, 2.97)          0.087                            1.45 (0.72, 2.96)             0.300                1.57 (0.93, 2.66)   0.095               
  Fractionation               Conventional versus Hypo   2.98 (1.52, 5.84)                **0.001**                     4.81 (1.77, 13.05)   **0.002**           3.25 (1.76, 6.01)   **≤.001**
  Breast volume (CC)          ≥Median versus \<Median    1.29 (0.74, 2.23)                0.371                         1.87 (0.96, 3.63)    0.067               1.38 (0.84, 2.27)   0.200

OR: odds ratio; CI: confidence interval; Model 1: multinomial logistic regression with generalized logit link function. Model 2: logistic regression.

Presence of moist desquamation.

Bold values indicate statistically significant findings at p \< 0.05.

John Wiley & Sons, Ltd

Using the NCI CTCAE grading scale, higher BMI (OR = 2.09; 95% CI = 1.15, 3.82), higher stage (OR = 1.82; 95% CI = 1.06, 3.11), ER‐positive/PR‐negative status (OR = 2.74; 95% CI = 1.26, 5.98), and conventionally fractionated regimens (OR = 3.25; 95% CI = 1.76, 6.01) were significantly associated with higher grade RT‐induced skin toxicity (2--3 vs. 0--1). After controlling for all predictors, age, race, and breast volume were not significant predictors of severe skin toxicity by either grading scale.

Discussion {#cam4608-sec-0007}
==========

In this prospectively followed tri‐racial/ethnic cohort of breast cancer patients receiving adjuvant RT to the intact breast after breast‐conserving surgery, the overall incidence of NCI CTCAE grade 2 or greater skin toxicity was 52%, and 21% developed moist desquamation, consistent with the majority of published series [1](#cam4608-bib-0001){ref-type="ref"}, [2](#cam4608-bib-0002){ref-type="ref"}, [3](#cam4608-bib-0003){ref-type="ref"}, [4](#cam4608-bib-0004){ref-type="ref"}, [5](#cam4608-bib-0005){ref-type="ref"}, [6](#cam4608-bib-0006){ref-type="ref"}, [7](#cam4608-bib-0007){ref-type="ref"}, [8](#cam4608-bib-0008){ref-type="ref"}. We identified higher BMI, higher disease stage, PR‐negative tumor status, and conventionally fractionated regimens as predictors for higher skin toxicity grade. Age, race, ethnicity, and breast volume did not predict for skin toxicity. Additionally, a more detailed skin toxicity scale designed to specifically capture desquamation identified BMI as a predictor specifically for moist desquamation, but not dry desquamation or degree of erythema, a finding the NCI CTCAE scale was not able to detect.

One of the most important findings of this series is that race and ethnicity were not associated with variation in skin toxicity. In our previously published series of patients receiving PMRT, the incidence of moist desquamation was much higher, 53.7% overall, and AA race was found to be a significant predictor of moist desquamation but not of higher grade skin toxicity by the CTCAE scale [10](#cam4608-bib-0010){ref-type="ref"}. In the current series, there was a nonsignificantly higher rate of severe skin toxicity in AA versus non‐AA patients -- 58 versus 50% for CTCAE grade 2--3 toxicity, and 28 versus 19% for moist desquamation. AA patients were more likely to have other potential risk factors for skin toxicity, including higher BMI, higher disease stage, and larger breast volume; when these factors were considered in multivariate analysis, race ultimately did not predict for skin toxicity grade or moist desquamation. There are two possible interpretations. One is that this study has limited statistical power to identify variation in skin toxicity by race, given the low incidence of moist desquamation and severe skin toxicity in patients receiving radiation to the intact breast. However, it is also possible that race only predicts for moist desquamation at the higher skin doses achieved using PMRT, and is not associated with skin toxicity grade in the postlumpectomy setting. We look forward to analysis of additional cohorts to determine if differences are seen with larger patient numbers and different populations.

It is also important to note that this cohort includes a large number of HW patients, who make up the majority (62%) of the non‐AA comparison group, demonstrating no increased risk of skin toxicity severity in this population as compared to NHW and AA patients.

The relationship between BMI and higher grade skin toxicity is supported by previous studies [6](#cam4608-bib-0006){ref-type="ref"}, [8](#cam4608-bib-0008){ref-type="ref"}, [9](#cam4608-bib-0009){ref-type="ref"}. However, our findings on multivariate analysis using the modified scale additionally demonstrated that BMI is specifically associated with moist desquamation, rather than dry desquamation or greater degree of erythema or hyperpigmentation. While both breast volume and BMI predicted for higher skin toxicity grade in univariate analysis, only BMI retained statistical significance on multivariate analysis, suggesting this is a more important predictor than breast volume. This finding likely relates the bolus effect of skin folds seen in obese patients, as well as the abrasive effect of friction within skin folds; nonobese patients with larger breasts often have fewer skin folds than obese patients, explaining why BMI may be more predictive than breast volume. Skin toxicity is usually addressed with one of any number of topical agents, or in some cases with subcutaneous amifostine, [6](#cam4608-bib-0006){ref-type="ref"}, [11](#cam4608-bib-0011){ref-type="ref"}, [12](#cam4608-bib-0012){ref-type="ref"}, but recent data suggest that a protective barrier approach may also reduce desquamation [13](#cam4608-bib-0013){ref-type="ref"}. The premise of the barrier film approach is that skin reaction forms from an accumulation of microabrasions on the skin surface, in tissue that is sensitized to injury by radiation. The finding that BMI is specifically correlated with moist desquamation points to a barrier approach as a potentially more effective approach in these patients, an important subject for future investigation.

Large breast separation (a surrogate for large breast volume and/or BMI) has long been considered a relative contraindication to hypofractionated treatment regimens, based on the concept that such patients are at higher risk of more severe skin reaction. One of the reasons for the risk of skin toxicity in patients with large breast separation has been the difficulty in achieving dose homogeneity in this setting, and the awareness that dosimetric "hotspots" are likely to increase the risk of desquamation [1](#cam4608-bib-0001){ref-type="ref"}. However, this series demonstrates that relatively homogeneous plans can be achieved even in patients with large breast volume and/or high BMI. About 40% of our patients were obese. Nonetheless, the mean percent of the breast volume receiving \>105% of prescription dose was 35%, and \>110% was 16%. Dosimetric factors were not associated with skin toxicity, possibly because reasonably homogeneous plans were achieved. The finding that higher BMI predicted for moist desquamation, whereas dosimetric factors did not, again suggests skin folds as an important underlying cause of moist desquamation.

The majority of data evaluating toxicity related to fractionation scheme has focused on late rather than acute toxicity. However, a recent large analysis from the Michigan Radiation Oncology Quality Consortium found that conventionally fractionated radiation was associated with higher skin toxicity grade compared to hypofractionated regimens [8](#cam4608-bib-0008){ref-type="ref"}, and our study corroborates this finding. The reasons for this likely relate to the lower total dose prescribed with hypofractionated regimens, and this finding lends greater support for the use of this approach in appropriately selected patients [8](#cam4608-bib-0008){ref-type="ref"}, [14](#cam4608-bib-0014){ref-type="ref"}.

There are a number of interesting findings in our analysis, in particular associations between skin toxicity and disease characteristics including stage and receptor status. It is interesting that PR‐negative status predicted for higher skin toxicity grade in this series, whereas in our series evaluating risk factors for skin toxicity in the setting of PMRT, PR‐negative status was protective. There is no clear explanation for these findings; we are not aware of any literature that identifies hormone receptors as a predictor of RT‐induced skin reaction [15](#cam4608-bib-0015){ref-type="ref"}. The fact that PR status emerged as a significant predictor in both series, but in opposite directions, suggests that it is possible that these relationships are treatment specific or related to the statistical limitations of these relatively small series. To better evaluate the relationship identified in this series, we conducted additional analyses and found that ER and PR status were significantly associated with each other on univariate analysis (data not shown); thus in the multivariate model we included ER and PR status as a combined variable, to avoid collinearity. PR status was analyzed as ER+/PR− versus ER+/PR+, and as ER−/PR− versus ER+/PR+ to account for this, and in the context of ER positivity, PR‐negative status retained its significance as a risk factor for more severe skin toxicity. Thus, it seems the strength of this relationship is maintained despite the collinearity of ER and PR. These relationships between PR status and skin toxicity may thus be a novel finding, which requires further investigation.

Our analysis also showed that more severe skin toxicity was associated with invasive disease as compared to DCIS, but not chemotherapy or hormone therapy. There may be underlying changes in the skin of the breast in the setting of invasive breast cancer or more locally advanced breast cancer that predispose to radiation sensitivity. It would seem logical that the skin toxicity grade would relate to the more frequent use of chemotherapy in patients with invasive disease, but there have been mixed findings on this correlation [16](#cam4608-bib-0016){ref-type="ref"}, [17](#cam4608-bib-0017){ref-type="ref"}, and these associations may also relate to the time interval between chemotherapy and radiation.

Overall this series identified a number of factors that were associated with skin reaction that are not readily explained, including relationships between tumor subtype, stage, and skin reaction. While there is no known mechanism for such relationships, we hypothesize that these findings may relate to patient factors such as inflammatory or other cytokines related to the various conditions -- obesity, presence of invasive breast cancer, and PR status, among others, that might link these factors to skin toxicity. Our prospective analysis also includes collection of genomic DNA, serum, and urine specimens at the start and completion of RT, and we are optimistic that future studies may begin to elucidate molecular and genetic mechanisms [18](#cam4608-bib-0018){ref-type="ref"}. Indeed, our preliminary analysis has uncovered a relationship between C‐reactive protein and skin reaction [19](#cam4608-bib-0019){ref-type="ref"}. However, the relationships identified in this study must be interpreted cautiously, and are simply hypothesis‐generating at this time.

In this series, the NCI CTCAE scale captured the majority of the findings that the modified scale did, however, the more nuanced analysis of the study scale was able to differentiate between factors that increased the risk of higher grade skin toxicity overall (including erythema, hyperpigmentation, and desquamation), as well as factors that specifically predict for moist desquamation. These findings lend additional support to the need to capture additional skin toxicity data beyond the CTCAE scale.

We continue to expand this study cohort and will conduct additional analyses as our data matures. With a rate of moist desquamation of 21%, we hope that we may be able to strengthen the statistical analysis and more clearly identify novel predictors of this endpoint as our series continues to grow over time. As a component of our study we are also collecting patient‐reported outcomes in the form of the Breast Cancer Treatment Outcome Scale (BC‐TOS) and we are currently conducting an analysis of quality of life (QOL) data in this patient cohort, relating QOL outcomes to acute skin toxicity factors, to help put the acute toxicities identified in this study in context of the patient‐reported outcomes and to guide priorities for future treatment decision making and intervention studies.
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